We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
101
Alector
ALEC
$198M
$316K 0.07%
+52,500
New +$343K
MLYS icon
102
Mineralys Therapeutics
MLYS
$2.41B
$310K 0.07%
+24,000
New +$296K
JVSAU
103
DELISTED
JVSPAC Acquisition Corp. Unit
JVSAU
$309K 0.07%
+30,000
New +$306K
GOOGL icon
104
Alphabet (Google) Class A
GOOGL
$4.33T
$302K 0.07%
+2,000
New +$286K
SPRB
105
Spruce Biosciences
SPRB
$129M
$287K 0.07%
+4,870
New +$1.24M
CNTX icon
106
Context Therapeutics
CNTX
$44.5M
$284K 0.06%
+205,934
New +$232K
DJT icon
107
CALL
Trump Media & Technology Group
DJT
$2.83B
$279K 0.06%
+4,500
New +$175K
SNY icon
108
Sanofi
SNY
$104B
$267K 0.06%
+5,500
New +$269K
TRML
109
DELISTED
Tourmaline Bio
TRML
$265K 0.06%
+11,560
New +$408K
CCOI icon
110
Cogent Communications
CCOI
$497M
$261K 0.06%
+4,000
New +$292K
IROHU
111
DELISTED
Iron Horse Acquisitions Corp Unit
IROHU
$255K 0.06%
25,000
– –
ZROZ icon
112
PIMCO 25+ Year Zero Coupon US Treasury Index Exchange-Traded Fund
ZROZ
$1.28B
$238K 0.05%
+3,000
New +$237K
VERU icon
113
Veru
VERU
$37.4M
$235K 0.05%
33,607
-16,393
-33% -$87.3K
OPCH icon
114
Option Care Health
OPCH
$3.56B
$235K 0.05%
+7,000
New +$227K
AQN icon
115
Algonquin Power & Utilities
AQN
$4.42B
$234K 0.05%
37,000
-13,000
-26% -$78.8K
ABVX
116
Abivax
ABVX
$11.4B
$215K 0.05%
+15,000
New +$193K
KZR
117
DELISTED
Kezar Life Sciences
KZR
$213K 0.05%
+23,662
New +$216K
AMLX icon
118
CALL
Amylyx Pharmaceuticals
AMLX
$2.54B
$210K 0.05%
74,100
+62,100
+518% +$812K
APLT
119
PUT
DELISTED
Applied Therapeutics
APLT
$205K 0.05%
+30,100
New +$135K
KTTA icon
120
Pasithea Therapeutics
KTTA
$16.9M
$201K 0.05%
+27,696
New +$197K
TLT icon
121
iShares 20+ Year Treasury Bond ETF
TLT
$41.7B
$189K 0.04%
+2,000
New +$189K
WVE icon
122
Wave Life Sciences
WVE
$1.2B
$185K 0.04%
+30,000
New +$150K
CYTK icon
123
CALL
Cytokinetics
CYTK
$10.4B
$175K 0.04%
2,500
-70,700
-97% -$5.47M
IMTX icon
124
Immatics
IMTX
$1.32B
$170K 0.04%
16,200
-5,800
-26% -$67.6K
GLRE icon
125
Greenlight Captial
GLRE
$506M
$167K 0.04%
13,385
-20,639
-61% -$241K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.